Thomas Gajewski, MD, PhD, University of Chicago Material Contribution to Immuno-Oncology

Thomas Gajewski, MD, PhD, University of Chicago Material Contribution to Immuno-Oncology

Thomas Gajewski, MD, PhD, AbbVie Foundation Professor of Cancer Immunotherapy in the Ben May Department for Cancer Research and Professor of Pathology and Medicine at the University of Chicago, was named by the European Society for Medical Oncology (ESMO) as the...
Monash Receives Another $76 Million for Medical Research Breaking the Record

Monash Receives Another $76 Million for Medical Research Breaking the Record

Australia’s National Health and Medical Research Council (NHMRC) awards Monash University over $75 million. This award is the largest among a total of over $400 million allocated to various research centers reports Federal Health Minister Greg Hunt. Medical research...
Cancer Treatment Centers of America Investigators Dose First Patient in Experimental Immuno-Oncology Clinical Trial

Cancer Treatment Centers of America Investigators Dose First Patient in Experimental Immuno-Oncology Clinical Trial

Cancer Treatment Centers of America® (CTCA) clinical investigators based in Phoenix have dosed the first patient in the first-in-human study of NKTR-255, a first-in-class immunotherapy. This Phase I clinical trial is designed to evaluate the safety and tolerability of...

Pin It on Pinterest